Wechselwirkungen · Evotaz
EVOTAZ 300 mg/150 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 30
HOS-221622 · Präparat HOS-216856
Plasma concentrations of pitavastatin may be increased if co-administered with EVOTAZ. rosuvastatin (10 mg single dose) rosuvastatin AUC: ↑ 242% Plasma concentrations of (atazanavir 300 mg once daily rosuvastatin Cmax: ↑ 958% rosuvastatin are increased when with cobicistat 150 mg once daily) rosuvastatin Cmin: Not calculated co-administered with atazanavir/cobicistat. atazanavir AUC: ↔ atazanavir Cmax:↔ When co-administration is atazanavir Cmin: ↑ 6% necessary, do not exceed 10 mg rosuvastatin daily, and clinical monitoring for safety (e.g., myopathy) is recommended. INHALED BETA AGONISTS salmeterol Co-administration with Co-administration of salmeterol EVOTAZ may result in increased with EVOTAZ is not concentrations of salmeterol and recommended (see section 4.4). an increase in salmeterol-associated adverse events.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rosuvastatin (HOS-086307) salmeterol (HOS-086285) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-10T17:52:00Z · SHA-256 40174e49ce0746a74379ea61b4f4b5adda6941da4dba06eb57dcc489e5e45bf8 · Passage 38ed1f22f8603b9d5943f763105956d5996a0315685ef55550cf19c173362fe7 · Zeichen 75934–77528 im Abschnitt